A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is
The aim of this study is survey of effects of Imatinib with dose 400 mg per day after 6 months in the patients with CML chronic phase. Between of 2010 -2014, fifty four patients with high risk CML referred to Taleghani hospital in Kermanshah, Iran. We used the questionnaire about adverse events (AEs) of Imatinib capsule (Cipla manufacture, India) in these patients. For grading AEs, We used Common Terminology Criteria for AEs (CTCAE) manuscript (low AE equals grade 1, 2: high AE equals 3, 4 anddoi:10.7324/japs.2015.50213 fatcat:2qdks23j6vcfjmkfaehpqw3iwu